$PSTX
Poseida Therapeutics, Inc.

2022 Q4 Form 10-Q Financial Statement

#000156459022037398 Filed on November 10, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3 2021 Q3
Revenue $10.05M $116.3M $0.00
YoY Change -67.82%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $9.368M $9.389M $9.066M
YoY Change -2.51% 3.56% 40.34%
% of Gross Profit
Research & Development $33.90M $35.14M $32.52M
YoY Change -13.3% 8.03% 20.39%
% of Gross Profit
Depreciation & Amortization $1.355M $1.350M $1.169M
YoY Change 14.54% 15.48% 69.42%
% of Gross Profit
Operating Expenses $43.27M $44.53M $41.59M
YoY Change -11.17% 7.06% 24.25%
Operating Profit $71.78M -$41.59M
YoY Change -272.59% 24.25%
Interest Expense -$1.975M $1.775M $837.0K
YoY Change 135.12% 112.07% -1.3%
% of Operating Profit 2.47%
Other Income/Expense, Net $2.170M $656.0K $3.000K
YoY Change 656.1% 21766.67% -103.26%
Pretax Income -$33.03M $70.66M -$42.42M
YoY Change -2348.2% -266.56% 23.28%
Income Tax $292.0K $300.0K $0.00
% Of Pretax Income 0.42%
Net Earnings -$33.32M $70.41M -$42.42M
YoY Change -2368.07% -265.97% 23.28%
Net Earnings / Revenue -331.49% 60.54%
Basic Earnings Per Share $0.92 -$0.68
Diluted Earnings Per Share -$0.39 $0.92 -$681.0K
COMMON SHARES
Basic Shares Outstanding 85.95M 85.78M 62.30M
Diluted Shares Outstanding 76.69M 62.30M

Balance Sheet

Concept 2022 Q4 2022 Q3 2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $282.5M $279.0M $197.8M
YoY Change 36.92% 41.04% -42.08%
Cash & Equivalents $81.38M $164.8M $197.8M
Short-Term Investments $201.1M $114.2M $0.00
Other Short-Term Assets $6.982M $7.677M $6.988M
YoY Change -7.5% 9.86% 20.48%
Inventory
Prepaid Expenses
Receivables $9.088M $38.47M
Other Receivables $0.00 $0.00
Total Short-Term Assets $298.6M $325.1M $204.8M
YoY Change 39.6% 58.76% -41.03%
LONG-TERM ASSETS
Property, Plant & Equipment $21.59M $21.75M $22.44M
YoY Change -2.1% -3.09% -54.01%
Goodwill $4.228M $4.228M
YoY Change 0.0%
Intangibles $1.320M $1.320M
YoY Change 0.0%
Long-Term Investments
YoY Change
Other Assets $1.055M $1.056M $3.961M
YoY Change -36.48% -73.34% 11.64%
Total Long-Term Assets $53.27M $55.35M $57.14M
YoY Change -3.9% -3.13% -1.27%
TOTAL ASSETS
Total Short-Term Assets $298.6M $325.1M $204.8M
Total Long-Term Assets $53.27M $55.35M $57.14M
Total Assets $351.8M $380.5M $261.9M
YoY Change 30.64% 45.26% -35.35%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.228M $3.426M $3.644M
YoY Change -75.14% -5.98% 190.13%
Accrued Expenses $28.05M $25.34M $25.36M
YoY Change 2.4% -0.1% -1.32%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $53.89M $48.97M $31.80M
YoY Change 24.35% 54.0% 6.81%
LONG-TERM LIABILITIES
Long-Term Debt $58.25M $58.16M $29.31M
YoY Change 98.42% 98.41% 0.88%
Other Long-Term Liabilities $2.091M $1.970M $50.61M
YoY Change 31.51% -96.11% 4582.15%
Total Long-Term Liabilities $60.34M $60.13M $29.31M
YoY Change 94.98% 105.13% -2.74%
TOTAL LIABILITIES
Total Short-Term Liabilities $53.89M $48.97M $31.80M
Total Long-Term Liabilities $60.34M $60.13M $29.31M
Total Liabilities $164.2M $164.2M $111.8M
YoY Change 45.22% 46.87% 2.24%
SHAREHOLDERS EQUITY
Retained Earnings -$470.9M -$437.5M -$408.3M
YoY Change 15.74% 7.15% 66.15%
Common Stock $658.6M $654.0M $558.5M
YoY Change 16.97% 17.1% 3.12%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $187.6M $216.3M $150.2M
YoY Change
Total Liabilities & Shareholders Equity $351.8M $380.5M $261.9M
YoY Change 30.64% 45.26% -35.35%

Cashflow Statement

Concept 2022 Q4 2022 Q3 2021 Q3
OPERATING ACTIVITIES
Net Income -$33.32M $70.41M -$42.42M
YoY Change -2368.07% -265.97% 23.28%
Depreciation, Depletion And Amortization $1.355M $1.350M $1.169M
YoY Change 14.54% 15.48% 69.42%
Cash From Operating Activities $2.403M $61.88M -$40.87M
YoY Change -71.64% -251.39% 39.4%
INVESTING ACTIVITIES
Capital Expenditures $260.0K -$1.703M -$365.0K
YoY Change -222.07% 366.58% -86.96%
Acquisitions
YoY Change
Other Investing Activities -$85.63M -$34.17M $37.50M
YoY Change -475822.22% -191.12% -114.69%
Cash From Investing Activities -$85.89M -$35.87M $37.14M
YoY Change 43946.15% -196.6% -114.39%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 58.00K 75.84M 1.855M
YoY Change -75.42% 3988.3% -99.1%
NET CHANGE
Cash From Operating Activities 2.403M 61.88M -40.87M
Cash From Investing Activities -85.89M -35.87M 37.14M
Cash From Financing Activities 58.00K 75.84M 1.855M
Net Change In Cash -83.43M 101.8M -1.882M
YoY Change -1079.9% -5511.48% -97.67%
FREE CASH FLOW
Cash From Operating Activities $2.403M $61.88M -$40.87M
Capital Expenditures $260.0K -$1.703M -$365.0K
Free Cash Flow $2.143M $63.58M -$40.51M
YoY Change -75.33% -256.96% 52.74%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Transition Report
DocumentTransitionReport
false
dei Document Type
DocumentType
10-Q
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei City Area Code
CityAreaCode
858
CY2022Q3 us-gaap Short Term Investments
ShortTermInvestments
114178000
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7677000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
22050000
CY2021Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1320000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.011
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
26177000
CY2022Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1320000
dei Entity Address City Or Town
EntityAddressCityOrTown
San Diego
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92121
dei Local Phone Number
LocalPhoneNumber
779-3100
dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7548000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
213873000
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
21748000
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
27000000
CY2022Q3 us-gaap Goodwill
Goodwill
4228000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
28171000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
26306000
us-gaap Operating Expenses
OperatingExpenses
123933000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
8000
dei Trading Symbol
TradingSymbol
PSTX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
85949385
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
164807000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
206325000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
97627000
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9066000
CY2021Q4 us-gaap Assets
Assets
269309000
CY2022Q3 us-gaap Assets
Assets
380481000
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
3426000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
8961000
CY2021Q4 pstx Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
23540000
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
6737000
CY2022Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-144000
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-437543000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-406859000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
216313000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
156211000
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
380481000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3462000
us-gaap Operating Expenses
OperatingExpenses
147166000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
71780000
pstx Increase Decrease In Operating Lease Right Of Use Assets
IncreaseDecreaseInOperatingLeaseRightOfUseAssets
2699000
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-1906000
pstx Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-3796000
pstx Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-2268000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-29175000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3664000
pstx Purchases Of Property And Equipment Included In Accounts Payable And Accrued Liabilities
PurchasesOfPropertyAndEquipmentIncludedInAccountsPayableAndAccruedLiabilities
68000
us-gaap Net Income Loss
NetIncomeLoss
-126443000
CY2022Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1400000
dei Entity Central Index Key
EntityCentralIndexKey
0001661460
CY2022Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Entity File Number
EntityFileNumber
001-39376
dei Entity Registrant Name
EntityRegistrantName
Poseida Therapeutics, Inc.
dei Entity Address Address Line1
EntityAddressAddressLine1
9390 Towne Centre Drive
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 200
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2022Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
38467000
CY2022Q3 us-gaap Assets Current
AssetsCurrent
325129000
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.92
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.68
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
76688382
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
62298243
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
6337000
CY2022Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
16732000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
43335000
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
25734000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
25504000
CY2022Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
58162000
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
29357000
CY2021Q4 pstx Deferred Cirm Grant Liability Noncurrent
DeferredCIRMGrantLiabilityNoncurrent
3992000
CY2022Q3 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
25287000
CY2021Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
9265000
CY2021Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
55000
CY2022Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1970000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1590000
CY2022Q3 us-gaap Liabilities
Liabilities
164168000
CY2021Q4 us-gaap Liabilities
Liabilities
113098000
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
85946414
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
85946414
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
62523596
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
62523596
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
9000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
6000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
563064000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
269309000
CY2022Q3 us-gaap Revenues
Revenues
116306000
us-gaap Revenues
Revenues
120441000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
35137000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
118995000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9389000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
44526000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-41590000
us-gaap Operating Income Loss
OperatingIncomeLoss
-26725000
us-gaap Operating Income Loss
OperatingIncomeLoss
-123933000
CY2022Q3 us-gaap Interest Expense
InterestExpense
1775000
CY2021Q3 us-gaap Interest Expense
InterestExpense
837000
us-gaap Interest Expense
InterestExpense
4395000
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
656000
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
3000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
688000
CY2021Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-42424000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-30432000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-126443000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
70409000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-42424000
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-12000
CY2021Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-1000
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-42425000
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.92
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.68
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
76287421
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
62298243
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4277000
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-12000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
216313000
dei Amendment Flag
AmendmentFlag
false
us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
true
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y4M20D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y4M20D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y8M12D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.013
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.005
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.034
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
52248000
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-42424000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-48845000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-126443000
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-2846548
CY2021Q4 us-gaap Goodwill
Goodwill
4228000
CY2022Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1056000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1661000
CY2022Q3 pstx Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
22073000
CY2021Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
4497000
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
48968000
CY2022Q3 pstx Deferred Cirm Grant Liability Noncurrent
DeferredCIRMGrantLiabilityNoncurrent
3992000
CY2022Q3 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
55000
CY2022Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
653991000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
32524000
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
41590000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-126448000
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.46
us-gaap Interest Expense
InterestExpense
2518000
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
70661000
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
252000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
252000
us-gaap Net Income Loss
NetIncomeLoss
-30684000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-144000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-5000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
70397000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-30828000
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.03
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.46
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.03
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
67235865
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
62144595
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
67235865
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
62144595
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
156211000
CY2022Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
681000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4867000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-58057000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
103702000
CY2022Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
32000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5234000
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-132000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-43036000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
65800000
CY2022Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
540000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
5223000
CY2022Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
75299000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
70409000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
261968000
CY2021Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
360000
CY2021Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
10000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-38314000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
227486000
CY2021Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
67000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4742000
CY2021Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-14000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-45705000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
186576000
CY2021Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1855000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4151000
CY2021Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-1000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-42424000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
150157000
us-gaap Profit Loss
ProfitLoss
-30684000
us-gaap Profit Loss
ProfitLoss
-126443000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
3817000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
3369000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-205000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-3000
us-gaap Share Based Compensation
ShareBasedCompensation
14378000
pstx Increase Decrease In Operating Lease Right Of Use Assets
IncreaseDecreaseInOperatingLeaseRightOfUseAssets
3602000
us-gaap Share Based Compensation
ShareBasedCompensation
12355000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-637000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-484000
pstx Amortization Accretion On Investment Securities Net
AmortizationAccretionOnInvestmentSecuritiesNet
474000
pstx Amortization Accretion On Investment Securities Net
AmortizationAccretionOnInvestmentSecuritiesNet
-133000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
38467000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
184000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2096000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-5536000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2882000
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-1536000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-606000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
228000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
2282000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
28257000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-111016000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2421000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
12000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
143792000
us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
30000000
us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
225000000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-117444000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
222579000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
1252000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
75299000
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
1450000
us-gaap Proceeds From Short Term Debt
ProceedsFromShortTermDebt
30000000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
105101000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2282000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-41518000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
113845000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
206325000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
83966000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
164807000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
197811000
pstx Purchases Of Property And Equipment Included In Accounts Payable And Accrued Liabilities
PurchasesOfPropertyAndEquipmentIncludedInAccountsPayableAndAccruedLiabilities
58000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
115000
us-gaap Interest Paid Net
InterestPaidNet
3470000
us-gaap Interest Paid Net
InterestPaidNet
2041000
us-gaap Net Income Loss
NetIncomeLoss
-30700000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-29200000
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-437500000
CY2022Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
279000000.0
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of consolidated financial statements in conformity with GAAP requires the Company to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. On an ongoing basis, the Company evaluates its estimates, which include, but are not limited to, estimates related to revenue, accrued expenses, research and development expenses, stock-based compensation expense and deferred tax valuation allowances. The Company bases its estimates on historical experience and other market-specific or relevant assumptions that it believes to be reasonable under the circumstances. Actual results may differ from those estimates or assumptions.</p>
pstx Number Of Reportable Segment
NumberOfReportableSegment
1
pstx Number Of Customer
NumberOfCustomer
2
us-gaap Variable Lease Payment
VariableLeasePayment
0
CY2021Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
13762000
us-gaap Revenue Performance Obligation Description Of Payment Terms
RevenuePerformanceObligationDescriptionOfPaymentTerms
Payment terms on invoiced amounts are typically 30 - 60 days
CY2022Q3 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0
CY2021Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0
CY2022Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
34579000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
31187000
CY2022Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
12831000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
9137000
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
21748000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
22050000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
3800000
CY2021Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1200000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
3400000
CY2022Q3 pstx Accrued Contract Research Services Current
AccruedContractResearchServicesCurrent
11094000
CY2021Q4 pstx Accrued Contract Research Services Current
AccruedContractResearchServicesCurrent
12292000
CY2022Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
7504000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
8760000
CY2022Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
3475000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2488000
CY2022Q3 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
22073000
CY2021Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
23540000
CY2022Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
151966000
CY2022Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
1000
CY2022Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
145000
CY2022Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
151822000
CY2021Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
176102000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
176102000
CY2022Q3 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
0
CY2021Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
0
CY2022Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
0
CY2021 pstx Contract With Customer Liability Amounts Received Invoiced
ContractWithCustomerLiabilityAmountsReceivedInvoiced
45000000
CY2021 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
-31238000
pstx Contract With Customer Liability Amounts Received Invoiced
ContractWithCustomerLiabilityAmountsReceivedInvoiced
148698000
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
-120441000
CY2022Q3 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
42019000
CY2022Q3 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
1800000
CY2022Q3 pstx Debt Instrument Final Payment Fee Accrued
DebtInstrumentFinalPaymentFeeAccrued
2000000.0
CY2022Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
300000
us-gaap Common Stock Voting Rights
CommonStockVotingRights
Each share of common stock is entitled to one vote.
CY2022Q3 pstx Common Stock Dividends Declared
CommonStockDividendsDeclared
0
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
9899707
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
9.57
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
3725101
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
3.67
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
94164
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.44
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
1567282
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
9.12
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
11963362
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.85
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
1409000
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
11963362
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
7.85
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
1409000
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
4720812
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
9.24
CY2022Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
619000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.63
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
6.32
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
100000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
3200000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
100000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1700000
CY2022Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
34000000.0
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4277000
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4151000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
14378000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
12355000
CY2022Q3 us-gaap Area Of Land
AreaOfLand
110000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
4400000
us-gaap Lessee Operating Lease Option To Extend
LesseeOperatingLeaseOptionToExtend
Certain of the Company’s manufacturing, laboratory and office space lease agreements include two options to extend the term for a period of five years each.
pstx Lessee Operating Lease Number Of Options To Extend Term
LesseeOperatingLeaseNumberOfOptionsToExtendTerm
2
CY2022Q3 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P5Y
us-gaap Operating Lease Expense
OperatingLeaseExpense
5400000
us-gaap Operating Lease Expense
OperatingLeaseExpense
4700000
us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
600000
us-gaap Operating Lease Payments
OperatingLeasePayments
6100000
CY2022Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P6Y6M
CY2022Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.089
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
1729000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
7057000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
6188000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
6374000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
5107000
CY2022Q3 pstx Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
16260000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
42715000
CY2022Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
10244000
CY2022Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
32471000
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
6737000
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
25734000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
70409000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-42424000
us-gaap Net Income Loss
NetIncomeLoss
-30684000
us-gaap Net Income Loss
NetIncomeLoss
-126443000
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
70409000
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-42424000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-30684000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-126443000
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
76287421
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
62298243
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
67235865
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
62144595
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
76688382
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
62298243
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
67235865
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
62144595
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.92
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.68
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.46
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.03
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.92
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.68
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.46
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.03
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
14457411
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8577960
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
300000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
300000
CY2022Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.004
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.008
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21

Files In Submission

Name View Source Status
0001564590-22-037398-index-headers.html Edgar Link pending
0001564590-22-037398-index.html Edgar Link pending
0001564590-22-037398.txt Edgar Link pending
0001564590-22-037398-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
ggagwvcoow0i000001.jpg Edgar Link pending
ggagwvcoow0i000002.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
pstx-10q_20220930.htm Edgar Link pending
pstx-20220930.xsd Edgar Link pending
pstx-ex101_92.htm Edgar Link pending
pstx-ex311_7.htm Edgar Link pending
pstx-ex312_8.htm Edgar Link pending
pstx-ex321_10.htm Edgar Link pending
pstx-ex322_6.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
pstx-20220930_cal.xml Edgar Link unprocessable
pstx-20220930_def.xml Edgar Link unprocessable
pstx-20220930_lab.xml Edgar Link unprocessable
pstx-20220930_pre.xml Edgar Link unprocessable
pstx-10q_20220930_htm.xml Edgar Link completed
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable